



26–29 June • World Trade &amp; Convention Centre

# COS and Affiliated Societies Annual Meeting & Exhibition 2003



## Scientific Program

### Day 2 / Jour 2 Friday, June 27 / Vendredi 27 juin

#### S Canadian Retina and Vitreous Society / Société canadienne de la rétine et du vitré

1030–1700

Location / Local : Highland 6

**Objectives:** The presentations are largely of a clinical research nature. The participants will have the opportunity to review and discuss novel medical and surgical techniques and applications to help determine when and how they might be included in their clinical practice.

**Objectifs :** L'exposé consiste surtout en une recherche clinique. Les participants auront l'occasion de revoir les nouvelles techniques et applications médicales et chirurgicales et d'examiner ensemble quand et comment ils pourraient les inclure dans leur pratique clinique.

*Guest / Invitée :*

Johanna M. Seddon, Boston, Massachusetts

#### Medical Retina I / Soins thérapeutiques de la rétine I

*Session chair / Présidence :*

Arif Samad

- 1030 **Clinical–biochemical correlations in Oguchi's disease**  
*Thaddeus Dryja*

- 1050 **Discussion**

- 1100 **Abstract A-1**

**Mutant frizzled-4 (FZD4) causes autosomal dominant familial exudative vitreoretinopathy with variable intrafamilial phenotype**

*J. Robitaille,\* M.L.E. MacDonald,  
A. Kaykas, L. Sheldahl, M.-P. Dube,  
D.L. Guernsey, B. Zheng, L.S. Siebert,  
A. Hoskin-Mott, M.J. Beis, S.N. Pimstone, B.S. Shastry, R.T. Moon, M.R. Hayden,  
Y.P. Goldberg, M.E. Samuels*

- 1107 **Abstract A-2**

**The effect of docosahexaenoic acid supplementation on macular function in a patient with a mutation in ELOVL4**

*I.M. MacDonald,\* M. Hébert, R.J. Yau,  
S. Flynn, J. Jumpsen, M. Suh,  
M.T. Clandinin*

- 1114 **Abstract A-3**

**Changes in multifocal electroretinography amplitude, but not timing, secondary to chloroquine and hydroxychloroquine toxicity**

*A. Bhargava,\* S.G. Coupland, P.J. Kertes, B.C. Leonard*

- 1121 **Discussion**

- 1130 **Abstract A-4**  
**Five-year outcomes of the Canadian proton radiation therapy experience** *K.E. Paton, L.A. Wittenberg\**
- 1137 **Abstract A-5**  
**Neovascular glaucoma following proton beam radiation therapy: risk factors, monitoring and treatment strategies**  
*K.E. Paton,\* L.A. Wittenberg*
- 1144 **Abstract A-6**  
**Bilateral exudative retinal detachment as initial presentation of sympathetic ophthalmia**  
*C.W. Chang,\* M.D.J. Greve, B.J. Hinz*
- 1151 **Discussion**

---

**1200–1330**

**Lunch / Déjeuner**

**Surgical Retina / Soins chirurgicaux de la rétine**

*Session chair / Présidence :*

Peter J. Kertes

- 1330 **Retinal detachment in developing countries**

*David Yorston*

- 1350 **Discussion**

- 1400 **Abstract A-7**

**Posterior vitreous detachment: Is the 6-week follow-up necessary?**

First prize, COS/Coherent-AMT Award for Excellence in Ophthalmic Research / Premier prix d'excellence SCO/Coherent-AMT en recherche ophtalmique

*K. Hasanee,\* S. Sharma*

- 1407 **Abstract A-8**

**The new 25-gauge sutureless vitrectomy: outcomes and complications**

*M.-J. Fredette,\* Y. Tardif, B. Cinq-Mars*

- 1414 **Abstract A-9**

**Massive peripapillary choroidal neovascularization: an indication for submacular surgery**

*P.J. Kertes*

- 1421 **Discussion**

- 1430 **Abstract A-10**

**Visual outcome of epiretinal membrane surgery with trypan blue**

*M. Perrier,\* M. Sébag*

- 1437 **Abstract A-11**

**Outcome of macular hole surgery using trypan blue to facilitate delamination of the internal limiting membrane**

*M. Perrier,\* M. Sébag*

- 1444 **The etiology of macular detachment in an optic nerve pit/coloboma**

*B. Hurley,\* P.J. Kertes*

- 1451 **Discussion**

---

**1500–1530**

**Break / Pause**

## **Medical Retina II / Soins thérapeutiques de la rétine II**

*Session chair / Présidence :*

Murray J. Erasmus

1530 **TBA**

*Johanna M. Seddon*

1550 **Discussion**

1600 **Abstract A-12**

**Can multifocal electroretinography be used to follow patients with age-related macular degeneration after photodynamic therapy and predict the need for retreatment?**

*M.-J. Fredette,\* H. Shekavat, G. Lalonde, B. Cinq-Mars, Y. Tardif, M. Malenfant, M. Hébert*

1607 **Abstract A-13**

**Does photodynamic therapy retreatment affect electroretinal function?**

*S.G. Coupland,\* B.C. Leonard, P.J. Kertes*

1614 **Abstract A-14**

**Off-label uses of photodynamic therapy**

*R. Varma,\* M.J. Erasmus, K. Colleaux*

1621 **Discussion**

1630 **Abstract A-15**

**Evaluation of active and clinically resolved central serous chorioretinopathy with multifocal electroretinography**

*L.A. Wittenberg,\* D. Maberley*

1637 **Abstract A-16**

**Micropulsed diode laser treatment for chronic idiopathic central serous chorioretinopathy**

*F. Ali,\* N. Armogan, J. Freudenthal*

1644 **Abstract A-17**

**Focal laser treatment of retinal angiomatic proliferations guided by high-speed indocyanine green imaging**

*T.M. Johnson,\* B.M. Glaser*

1651 **Discussion**